Published in Cancer Epidemiol Biomarkers Prev on January 01, 2010
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
MYC and Breast Cancer. Genes Cancer (2010) 1.66
N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med (2012) 1.24
Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One (2013) 1.21
Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS One (2012) 1.14
Nuclear β-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer. J Transl Med (2013) 1.09
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res (2010) 1.07
Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Sci Rep (2015) 1.04
Regulation of Tcf7l1 DNA binding and protein stability as principal mechanisms of Wnt/β-catenin signaling. Cell Rep (2013) 1.03
Small interfering RNA-mediated downregulation of beta-catenin inhibits invasion and migration of colon cancer cells in vitro. Med Sci Monit (2012) 0.94
Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner. PLoS One (2013) 0.93
Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells. J Biol Chem (2011) 0.92
β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One (2015) 0.87
Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. PLoS One (2013) 0.84
Hypothyroidism reduces mammary tumor progression via Β-catenin-activated intrinsic apoptotic pathway in rats. Histochem Cell Biol (2017) 0.81
Transcriptional shift identifies a set of genes driving breast cancer chemoresistance. PLoS One (2013) 0.80
Ductal barriers in mammary epithelium. Tissue Barriers (2013) 0.80
Potential canonical wnt pathway activation in high-grade astrocytomas. ScientificWorldJournal (2012) 0.80
Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity. Oncotarget (2015) 0.79
Simultaneous disruption of estrogen receptor and Wnt/β-catenin signaling is involved in methyl amooranin-mediated chemoprevention of mammary gland carcinogenesis in rats. Mol Cell Biochem (2013) 0.78
HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations. Clin Exp Metastasis (2015) 0.77
Mammary Development and Breast Cancer: A Wnt Perspective. Cancers (Basel) (2016) 0.77
The role of adhesion molecules as biomarkers for the aggressive prostate cancer phenotype. PLoS One (2013) 0.77
Multicentric and multifocal versus unifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology. BMC Cancer (2013) 0.77
Clinical implications of β-catenin protein expression in breast cancer. Int J Clin Exp Pathol (2015) 0.77
MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer. Oncotarget (2016) 0.76
β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Mol Carcinog (2015) 0.76
Protein mislocalization: mechanisms, functions and clinical applications in cancer. Biochim Biophys Acta (2014) 0.76
Loss of Core 1-derived O-Glycans Decreases Breast Cancer Development in Mice. J Biol Chem (2015) 0.76
The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cells. Oncotarget (2015) 0.76
CK1δ: an exploitable vulnerability in breast cancer. Ann Transl Med (2016) 0.75
Somatic mutation patterns and compound response in cancers. BMB Rep (2013) 0.75
Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium. Oncogene (2016) 0.75
Targeting the perpetrator: breast cancer stem cell therapeutics. Curr Drug Targets (2010) 0.75
Association among the expression of β-catenin, cyclin D1 and estrogen receptor-β in human breast cancer. Exp Ther Med (2015) 0.75
Epigallocatechin gallate inhibits the growth of MDA-MB-231 breast cancer cells via inactivation of the β-catenin signaling pathway. Oncol Lett (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Cyclin D as a therapeutic target in cancer. Nat Rev Cancer (2011) 5.76
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A (2010) 2.67
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A (2003) 2.31
Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One (2007) 2.26
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol (2009) 2.21
Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat (2003) 2.14
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res (2009) 1.98
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 1.95
Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol (2009) 1.94
Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell (2012) 1.91
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer (2010) 1.89
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res (2003) 1.81
DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol (2002) 1.78
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer (2005) 1.73
Cyclins and breast cancer. J Mammary Gland Biol Neoplasia (2004) 1.73
Cell cycle control in breast cancer cells. J Cell Biochem (2006) 1.68
Molecular biology of lung cancer. J Thorac Dis (2013) 1.67
Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res (2004) 1.65
Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res (2010) 1.62
Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int (2013) 1.55
EphB4 expression and biological significance in prostate cancer. Cancer Res (2005) 1.53
Molecular markers of prostate cancer outcome. Eur J Cancer (2005) 1.52
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res (2005) 1.52
Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res (2005) 1.48
Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer (2003) 1.47
Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res (2003) 1.43
Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One (2008) 1.42
Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci U S A (2005) 1.41
The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints. Cell Cycle (2007) 1.36
EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response. J Biol Chem (2002) 1.34
Therapeutic targets in triple negative breast cancer. J Clin Pathol (2013) 1.33
Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol (2009) 1.32
The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res (2005) 1.32
Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem (2005) 1.32
Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res (2008) 1.30
Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol (2002) 1.28
Edd, the murine hyperplastic disc gene, is essential for yolk sac vascularization and chorioallantoic fusion. Mol Cell Biol (2004) 1.28
Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol (2008) 1.28
Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology (2009) 1.27
Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div (2010) 1.27
The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene (2002) 1.26
Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One (2009) 1.25
Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res (2011) 1.25
EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene (2003) 1.23
c-Myc overexpression and endocrine resistance in breast cancer. J Steroid Biochem Mol Biol (2006) 1.22
Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer (2013) 1.22
Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res (2002) 1.21
EDD mediates DNA damage-induced activation of CHK2. J Biol Chem (2006) 1.21
Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res (2004) 1.21
Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1. Oncogene (2005) 1.20
Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res (2011) 1.18
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res (2009) 1.17
Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol (2011) 1.17
ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol (2012) 1.16
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res (2009) 1.16
Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol (2009) 1.16
Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Res (2011) 1.14